Skip to main content
SpringerLink
Log in

Antidementiva

  • Chapter
Arzneiverordnungs-Report 2013

Zusammenfassung

Die Demenz ist eine Krankheit des höheren Lebensalters und hat sich durch den steigenden Anteil der älteren Bevölkerung in vielen Industrieländern zu einem großen Gesundheitsproblem entwickelt. Auch in den Entwicklungsländern ist in den nächsten Dekaden ein Zuwachs an Demenzpatienten zu erwarten. Häufigste Ursache ist die Alzheimersche Krankheit. Die Prävalenz nimmt ab dem 60. Lebensjahr rasch zu und erreicht bei 85jährigen 24–33% der Bevölkerung (Übersicht bei Ballard et al. 2011). Etwa 70% des Krankheitsrisikos ist genetisch bedingt. Bei 10% der Demenzkranken liegen potentiell reversible Grundkrankheiten vor, die sich nach rechtzeitiger Diagnose und anschließend spezifischer Therapie teilweise oder vollständig rückbilden können.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115.

    Google Scholar 

  • Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer’s Disease Cooperative Study (2003): Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289: 2819–2826.

    Google Scholar 

  • Aisen PS, Vellas B, Hampel H (2013): Moving towards early clinical trials for amyloidtargeted therapy in Alzheimer’s disease. Nat Rev Drug Discov 12: 324.

    Article  PubMed  CAS  Google Scholar 

  • Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011): Alzheimer’s disease. Lancet 377: 1019–1031.

    Article  PubMed  Google Scholar 

  • Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115.

    Article  CAS  Google Scholar 

  • Birks J (2006): Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.

    Google Scholar 

  • Birks J, Grimley Evans J (2006): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003120.

    Google Scholar 

  • Birks J, Harvey RJ (2006): Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD001190.

    Google Scholar 

  • Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE (2009): Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2: CD001191.

    Google Scholar 

  • Blennow K, Hampel H, Weiner M, Zetterberg H (2010): Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131–144.

    Article  PubMed  CAS  Google Scholar 

  • Blennow K, de Leon MJ, Zetterberg H (2006): Alzheimer’s disease. Lancet 368: 387–403.

    Article  PubMed  CAS  Google Scholar 

  • Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM; AV45-A07 Study Group (2011): Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305: 275–283.

    Google Scholar 

  • Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C (2ß12): Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease. Dement Geriatr Cogn Disord 33: 341–353.

    Google Scholar 

  • Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403.

    Article  PubMed  CAS  Google Scholar 

  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Deutsche Gesellschaft für Neurologie (2009): S3-Leitlinie Demenzen. Internet: www.dgn.org/images/stories/dgn/pdf/s3_leitlinie_demenzen.pdf

  • Flicker L, Grimley Evans G (2001): Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011.

    Google Scholar 

  • Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group (2009): Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302: 2557–2564.

    Google Scholar 

  • Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010): Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9: 560–574.

    Article  PubMed  CAS  Google Scholar 

  • Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE (2008): Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 3: 211–225.

    PubMed  CAS  Google Scholar 

  • Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O’Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012): Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366: 893–903.

    Article  PubMed  CAS  Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2007): Nutzenbewertung von Cholinesterasehemmern bei Patienten mit Alzheimer Demenz, auch im Vergleich mit anderen Therapieoptionen. Im Internet unter: www.iqwig.de/download/A05-19A_Abschlussbericht_Cholinesterasehemmer_bei_Alzheimer_Demenz.pdf

  • Janßen IM, Sturtz S, Skipka G, Zentner A, Velasco Garrido M, Busse R (2010): Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr 160: 539–546.

    Article  PubMed  Google Scholar 

  • Loy C, Schneider L (2006): Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD001747.

    Google Scholar 

  • McShane R, Areosa Sastre A, Minakaran N (2006): Memantine for dementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154.

    Google Scholar 

  • Muayqil T, Camicioli R (2012): Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer’s disease and other dementias. Dement Geriatr Cogn Dis Extra 2: 546–572.

    Article  PubMed  Google Scholar 

  • National Institute for Health and Clinical Excellence (2011): NICE technology appraisal guidance 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of NICE technology appraisal guidance 111). Internet: www.nice.org.uk/nicemedia/live/13419/53619/53619.pdf

  • Neugroschl J, Sano M (2010): Current treatment and recent clinical research in Alzheimer’s disease. Mt Sinai J Med 77: 3–16.

    Article  PubMed  Google Scholar 

  • Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer’s Disease Cooperative Study Group (2005): Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388.

    Google Scholar 

  • Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008): Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379–397.

    Article  PubMed  Google Scholar 

  • Reines SA, Block GA, Morris JC, Liu G, Nessly ML et al (2004): Rofecoxib. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66–71.

    Article  PubMed  CAS  Google Scholar 

  • Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group (2012): Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11: 851–859.

    Google Scholar 

  • Vlad SC, Miller DR, Kowall NW, Felson DT (2008): Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70: 1672–1677.

    Article  PubMed  CAS  Google Scholar 

  • Winblad B (2005): Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11: 169–182.

    Article  PubMed  CAS  Google Scholar 

  • Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R (2007): A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22: 456–567.

    Article  PubMed  Google Scholar 

  • Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS; The GAL-INT-11/18 Study Group (2008): Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70: 2024–2035.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Im Neuenheimer Feld 366, 69120

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2013). Antidementiva. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation